Valneva Se (VALN) has released an update.
Valneva SE has renegotiated its loan terms with investment firms Deerfield and OrbiMed, deferring reimbursements of its first $100 million loan tranche to January 2026, an 18-month extension from the original July 2024 start date. The maturity of this tranche will still be in the first quarter of 2027, and the terms for the second tranche remain unchanged. The company views this extension as a strategic move to strengthen its cash position as it anticipates profitability following the success of its Lyme disease vaccine program.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
